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Abstract
Background: ST-246H is an antiviral, orally bioavailable small molecule in clinical development for treatment of
orthopoxvirus infections. An intravenous (IV) formulation may be required for some hospitalized patients who are unable to
take oral medication. An IV formulation has been evaluated in three species previously used in evaluation of both efficacy
and toxicology of the oral formulation.
Methodology/Principal Findings: The pharmacokinetics of ST-246 after IV infusions in mice, rabbits and nonhuman primates
(NHP) were compared to those obtained after oral administration. Ten minute IV infusions of ST-246 at doses of 3, 10, 30, and
75 mg/kg inmiceproduced peakplasmaconcentrations ranging from 16.9to238 mg/mL. Eliminationappeared predominately
first-order and exposure dose-proportional up to 30 mg/kg. Short IV infusions (5 to 15 minutes) in rabbits resulted in rapid
distributionfollowedbyslowerelimination.IntravenousinfusionsinNHPwereconductedatdosesof1to30 mg/kg.Thelength
of single infusions in NHP ranged from 4 to 6 hours. The pharmacokinetics and tolerability for the two highest doses were
evaluated when administered as two equivalent 4 hour infusions initiated 12 hours apart. Terminal elimination half-lives in all
speciesfororalandIVinfusionsweresimilar.Dose-limitingcentralnervoussystemeffectswereidentifiedinallthreespeciesand
appeared related to high Cmax plasma concentrations. These effects were eliminated using slower IV infusions.
Conclusions/Significance: Pharmacokinetic profiles after IV infusion compared to those observed after oral administration
demonstrated the necessity of longer IV infusions to (1) mimic the plasma exposure observed after oral administration and
(2) avoid Cmax associated toxicity. Shorter infusions at higher doses in NHP resulted in decreased clearance, suggesting
saturated distribution or elimination. Elimination half-lives in all species were similar between oral and IV administration. The
administration of ST-246 was well tolerated as a slow IV infusion.
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Introduction
Variola virus (Strain Harper DQ441430) causes human
smallpox and is highly contagious with a mortality rate of
approximately 30% [1]. Although smallpox was eradicated after a
highly successful vaccination campaign [2], there is reason to be
concerned about either deliberate or accidental re-introduction
into the human population [3]. In addition, there are three other
orthopoxvirus species (monkeypox virus strain Zaire NC 003310,
vaccinia virus strain Western Reserve NC 006998, and cowpox
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cause significant disease [4–6]. While these viruses are less
pathogenic than variola virus, they retain the capacity to cause
serious illnesses and even death [7,8].
There are currently no approved therapeutic treatments for
orthopoxvirus infections, although cidofovir, a nephrotoxic drug
that is approved for CMV retinitis, has shown activity against
orthopoxviruses in vitro and in vivo in animal models [9–12].
Cidofovir has been administered for treatment of orthopoxvirus-
related illness [13–16]. In order to avoid kidney toxicity and death
(as described in the package insert) cidofovir must be co-
administered with probenecid and hydration therapy [17–19].
Oral prodrugs of cidofovir are currently being developed to
mitigate kidney toxicity and improve therapeutic properties of the
molecule [20]. Vaccines to protect against orthopoxvirus infection
have been approved by the FDA, but the high frequency of serious
adverse events associated with the vaccine and relatively low risk of
infection have limited their use [21]. Currently, only military
personnel being deployed to areas perceived to be at high risk for
bioterrorism and laboratory workers exposed to orthopoxviruses
are being vaccinated [22]. If an orthopoxvirus outbreak occurred,
exposed individuals would have to be treated with IV cidofovir
(and likely vaccinia immune globulin (VIG)), to mitigate disease
until vaccine could be deployed. Moreover, post-exposure
vaccination is less effective at altering the disease course after
the fourth day of infection; thus, effective antiviral treatment
would be the only viable option to treat exposed individuals [23].
ST-246 (Tecovirimat: 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-
octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benza-
mide) is a novel, orally available small molecule that specifically
inhibits viral egress [24,25]. The target of ST-246 has been identified
as the product of the F13L gene in vaccinia virus [24], which is highly
conserved among all orthopoxviruses, particularly in the region of the
gene targeted by ST-246 [26]. Reported EC50 values against different
poxviruses in vitro range from .007 to 0.16 mg/mL [27]. In vivo studies
have demonstrated potent efficacy against vaccinia virus, cowpox
virus and ectromelia virus [28] in mice, providing optimal efficacy at
a dose of 100 mg/kg. Additional in vivo efficacy has been demon-
strated in a ground squirrel model of monkeypox virus [29],
rabbitpox virus in rabbits [30] and variola virus and monkeypox in
NHP [31,32], at daily doses of 100, 40, 10, and 3 mg/kg, respectively
[33].
Oral, nonclinical safety studies have demonstrated safety
through three months daily administration in mice and NHP. In
NHP, the highest dose evaluated in the 3 month safety study,
300 mg/kg, was considered the No Observed Effect Level
(NOEL), due to the lack of any observed effect, and was 100-
fold higher than the efficacious dose in NHP of 3 mg/kg after
infection with monkeypox virus [32]. Oral bioavailability has been
estimated to be near 50%, with limited metabolism and largely
biliary excretion observed in a mass balance study in mice [34]. In
parallel with the animal efficacy studies, human safety evaluation
of ST-246 has demonstrated that oral administration for 21 days is
safe, with no serious adverse events having been reported after
administration to healthy adults [35]. Exposure to orally
administered ST-246 is dose proportional at lower doses, but
absorption appears to become saturating at higher doses [34].
Steady-state appeared to be reached after 6 days of administration,
consistent with the estimated 20 hour terminal elimination half-life
[34]. The accumulation index was estimated to be approximately
20% for daily dosing, indicating very little accumulation at steady-
state [34]. The long terminal elimination half-life and high
therapeutic index readily allow for single daily oral administration
in animal models of disease, as well as in humans [35].
During the short time that ST-246 has been in clinical
evaluation, there have been several occasions in which ST-246
has been requested for emergency use. In two of those cases, oral
administration was not the optimal route of administration. In the
first case [5], the patient was a young child who had been infected
with vaccinia virus after coming in close contact with his father,
who had received the smallpox vaccine. The child developed
severe eczema vaccinatum, and after unsuccessful treatment with
Vaccinia Immune Globulin Intravenous (VIGIV), was adminis-
tered ST-246. Based on the child’s inability to swallow a pill and
the need to use a very low dose due to his low body weight, the
ST-246 was administered via a nasogastric tube [36]. In the
second instance, a 20-year old male had developed progressive
vaccinia after receiving cancer chemotherapy subsequent to
having received the smallpox vaccine. The patient was taking
ST-246 with little to no food, significantly decreasing absorption
[33,37]. In both of these cases, an IV formulation would have
facilitated dose administration and simplified any required dose
adjustment.
A new formulation has been developed for IV administration of
ST-246. The tolerability and pharmacokinetics of this formulation
have been evaluated in mice, rabbits and NHP in order to
determine the optimal administration strategy. The results are
compared with the pharmacokinetics observed after oral admin-
istration.
Methods
Materials
All materials used in the conduct of these studies were reagent
grade, or higher, unless specifically noted below. The source,
where a material may not be readily available, is noted.
Study designs and animal in-life studies
Ethics Statement. The in-life portions of the experiments
were conducted at several different laboratories, all of which
conducted studies according to all Federal, State, and local
guidelines for the use of animals in research and were reviewed
and approved by their respective Institutional Animal Care and
Use Committees prior to conduct of the studies. Oral studies were
conducted at MPI Research in Mattawan, MI. The protocols for
these studies at MPI were reviewed and approved by MPI
Research IACUC before each study. The IACUC approval ID
numbers were as follows: (1) 1151-021 (mice); (2) 1151-023
(rabbits); and (3) 1151-065 (NHP). Those studies were conducted
in compliance with the Testing Facility Animal Welfare Assurance
(A3181-01) filed with NIH. The study in NHP did not require any
procedures that were anticipated to cause more than slight or
momentary pain or distress to animals, such as the collection of
blood samples. NHP were observed cageside at least twice daily for
any signs of morbidity, mortality, injury, and availability of food
and water. Any animals found in poor health were to be
monitored further for possible treatment and/or euthanasia. The
IV studies in mice and rabbits were conducted at Oregon State
University and the protocol approved by their IACUC for those
studies was Number 3871. The IV infusion studies in NHP were
conducted at Charles River Laboratories under approved protocol
numbers (1) MDA00051; (2) 20002163; and (3) 20002757.
The protocols for IV infusions in NHP conducted at Charles
River were reviewed and approved by PCS-NV IACUC before
the study. Those studies were conducted in compliance with the
Testing Facility Animal Welfare Assurance (A4112-01) filed with
NIH. In an effort to minimize discomfort during the infusions, the
NHP had surgery to install vascular access ports (VAP) and were
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infusion was carried out without the need to restrain the NHP
during the process, except for brief intervals during which blood
samples were taken. NHP were observed cageside at least twice
daily for any signs of morbidity, mortality, injury, and availability
of food and water. Any animals found in poor health were to be
monitored further for possible treatment and/or euthanasia. All
studies with nonhuman primates complied and followed applicable
sections of the Final Rules of the Animal Welfare Act regulations
(Code of Federal Regulations, Title 9), the Public Health Service Policy
on Humane Care and Use of Laboratory Animals from the Office of
Laboratory Animal Welfare, and the Guide for the Care and Use of
Laboratory Animals from the National Research Council. The NHP
studies were not terminal studies so all animals were released to
their respective colonies at the end of the studies.
Oral Studies. ST-246 was administered by oral gavage as a
methylcellulose suspension formulation with 1% Tween 80 to
BALB/c mice (Charles River), New Zealand White (NZW) rabbits
(Harlan), and cynomolgus monkeys (NHP, Harlan). NHP were
administered ST-246 immediately after feeding to increase the
bioavailability [33]. Female BALB/c mice were administered the
suspension formulation via oral gavage at doses of 30, 100, 300,
and 1000 mg/kg. Concentrations of ST-246 were measured by
taking blood samples from three mice at each of the following time
points: 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post dose.
Three male and three female NZW rabbits were administered ST-
246 orally as a suspension formulation at a dose of 100 mg/kg.
Blood was collected at the following time points for determination
of ST-246 concentration: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours
after administration. Three male and three female NHP per dose
group were administered the following oral doses of ST-246 in the
fed state: 0.3, 3, 10, 20, and 30 mg/kg. These doses were
administered daily for 14 days. Only data from Day 1 of this study
are presented here. Blood samples were collected predose and at
0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours after dose administration to
measure ST-246 concentration. Blood samples were collected into
Na Heparin tubes and kept on ice until the tubes were centrifuged
at low speed to collect the plasma. Plasma was transferred into new
tubes and stored at 270uC until bioanalysis.
IV infusion studies. The pharmacokinetics and tolerability
of a solution formulation of ST-246 administered by IV infusion
were evaluated in three animal species: female BALB/c (Charles
River) and CD-1 mice (Charles River), NZW rabbits (Harlan), and
cynomolgus monkeys (Charles River).
A slow push (5 minute) IV injection of a solution formulation of
ST-246 was administered to a small number of catheterized
female BALB/c mice at doses of 3, 30, and 100 mg/kg. Although
attempts were made to collect blood samples, patency difficulties
in the catheters limited the number of mice per time point. After a
study confirmed that the pharmacokinetics for BALB/c and CD-1
mice were very similar (data not shown), additional IV studies
were conducted in the CD-1 mouse strain. A 10-minute IV
infusion of ST-246 was given via a surgically implanted jugular
cannula at doses of 3, 10, 30, and 75 mg/kg to catheterized naı ¨ve
female CD-1 mice. Blood samples were collected at 5, 10 (end of
infusion), 20, 30 minutes, and 1, 2, 4, 8, 24 hours post dose. Blood
samples for each time point were collected from three animals as
terminal bleeds.
In rabbits, ST-246 was infused via the marginal ear vein at doses
of 3,30,and 60 mg/kgover a 5-minute periodand at 3 mg/kgover
a 15-minute period followed by blood sampling at multiple times in
order to generate complete plasma concentration time curves.
Blood samples were collected via the central ear artery or marginal
ear vein opposite to the site of injection. Two male and two female
rabbits were used for each dose group. For the 5-minute slow push
IV injection, blood samples were collected at 10 minutes (5 minutes
after the end of the injection), 20 and 30 min, 1, 2, 4, 8, and
24 hours after administration. Blood samples for the 15-minute IV
infusion were taken at the end of the infusion (15 minutes), 25 and
45 minutes, and 1, 2, 4, 8, and 24 hours after the beginning of the
infusion.
NHP were prepared for ST-246 administration by surgical
implantation of a catheter in the femoral vein that was routed to a
subcutaneous port. Doses of 1, 3, 10, 20, and 30 mg/kg were
infused over 4 hours to groups consisting of two male and two
female NHP. Two additional groups were administered the 20 and
30 mg/kg doses over 6 hours. For the 4 hour IV infusion group,
blood was collected for ST-246 analysis at the following time
points: 0.5, 1, 2, 4 (end of infusion), 4.25, 4.5, 5, 6, 8, 12, 16, 20,
24, and 48 hours after the start of the infusion. For the 6-hour IV
infusion, the samples were collected at the following time points: 1,
2, 4, 6 (end of infusion), 6.25, 6.5, 8, 10, 12, 16, 20, 24, and
48 hours after initiation of dose administration. Blood samples
were collected at multiple time points to allow complete
characterization of the plasma concentration time curve and
estimate the pharmacokinetic parameters. Two groups of 4 males
and 4 females were used in a second study that was conducted
after a 10 day washout. In the second study, the pharmacokinetic
parameters were characterized over the course of a single day
twice daily (BID) regimen for doses of 10 and 15 mg/kg that were
infused over two 4 hour infusion periods initiated 12 hours apart.
The total daily doses were 20 and 30 mg/kg, equivalent to the two
highest doses that had been evaluated during both 4 and 6 hour
IV infusions. For the BID study, blood was collected at the
following time points for ST-246 concentration determination:
0.5, 2, 4 (end of first infusion), 4.5, 6, 8, 12, 12.5, 14, 16 (end of
second infusion), 16.5, 18, 20, 24, 32, 36 and 60 hours after the
beginning of infusion of the first dose. In all cases blood was
collected by venipuncture using a site different than that used for
dosing (not via the catheter). Blood samples were collected into Na
Heparin tubes and kept on ice until the tubes were centrifuged at
low speed to collect the plasma. Plasma was transferred into new
tubes and stored at 270uC until bioanalysis.
Tolerability and toxicological evaluation
Cageside observations were made throughout all of these studies
for general appearance, behavior, mortality and moribundity.
Preclinical evaluations for adverse events (AEs) such as vital sign
measurements, physical examinations, and neurologic exams were
assessed throughout the studies in NHP.
Bioanalytical methods
ST-246 concentrations in mice, rabbit and NHP plasma were
measured using a liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS) method. Blank plasma for calibration curves
and quality control samples were purchased from Bioreclamation,
Inc. (Westbury, NY). Two different extraction methods were used
over the course of these studies. The second method, liquid-liquid
extraction, was validated after the initial protein precipitation
method, in order to extend HPLC column life. Both methods were
validated following the FDA bioanalytical validation guidelines
[38] and met FDA requirements for intra- and inter-assay
precision of within 15% relative standard deviation for all
validations. In one method, the extraction of ST-246 from plasma
was carried out by simple protein precipitation by the addition of 9
parts methanol (450 mL) containing the isotopic internal standard
to 1 part (50 mL) plasma sample. After high speed centrifugation
100 mL of supernatant was added to 200 mL of a compensation
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methanol; 36:55, v/v) and directly injected onto the LC-MS.
The second extraction method was a liquid-liquid extraction
(LLE) method. Plasma samples were diluted 1:1 with methanol
containing internal standard and three volumes of water added.
These mixtures were vortexed and the entire volume transferred to
the extraction plate (Biotage SLE, 200 mg). Minimal vacuum was
applied to load the samples and then allowed to stand for
5 minutes. Methyl tertiary-butyl ether was added to all wells
(500 mL/well) and eluted with minimal vacuum. The solvent was
evaporated to dryness under nitrogen (set at 50uC and 30–40 L/
min). The samples were reconstituted (0.05% acetic acid and
0.05% ammonium hydroxide in methanol/water; 65:35, v/v) by
gently vortexing the plate afterwards.
The chromatographic separation was performed using a
Phenyl-Hexyl column (5062.0 mm, 5 mm, Phenomenex) with a
Securityguard column, using 0.05% ammonium hydroxide and
0.05% acetic acid in MeOH/H2O (65:35,v/v) at a flow rate of
400 mL/min for the mobile phase. A 3200 (or 4000) Qtrap (AB
Sciex) mass spectrometer was tuned to the multiple reaction
monitoring (MRM) mode to monitor the m/z transitions, 375.0/
283.2 for ST-246 and m/z 341.1/248.8 for the internal standard,
in negative ion mode. The MS/MS response was (1/x
2) weighted
linearly over the concentration range from 5.00 to 2000 ng/mL.
The accuracy and precision of the method were within the
acceptable limits of 620% at the lower limit (5.0 ng/mL) of
quantitation and 615% at other concentrations.
Pharmacokinetic Analysis
Pharmacokinetic parameters were analyzed with WinNonlin
Phoenix version 6.1 (Pharsight, Mountain View, CA) software
using noncompartmental analysis. The following parameters were
estimated: terminal elimination half-life (t1/2=ln(2)/lz, where lz is
the first order rate constant associated with the terminal (log-
linear) portion of the curve), the area under the curve
(AUClast=Area under the curve from the time of dosing to the
last measurable concentration), the area under the curve
extrapolated to infinity (AUC0-inf=AUClast+Clast/lz), clearance
(CL=Dose/AUC), and the steady state volume of distribution
(Vss=Amount in body/Concentration at steady state). The peak
plasma concentrations (Cmax) and the time to peak plasma
concentration (Tmax) were determined directly from the observed
data.
Statistical Analysis
Untransformed and dose-normalized data for Cmax and AUC 0-inf,
and dose-linearity for clearance were analyzed using the JMP9.0
program (SAS Corporation, Cary, NC), which is based on the one-
way analysis of variance (ANOVA) regression model, in order to
evaluate dose linearity and dose proportionality. Gender differences
within the same dose group were evaluated using Student’s t-test. A
value of p,0.05 was considered statistically significant.
Results
Mouse Studies
Tolerability. Preliminary bolus IV injections of ST-246 in
BALB/c mice resulted in some dose-related toxicity and mortality
at the highest dose of 34 mg/kg. A slower (5-minute push) IV
injection resulted in some clinical signs of labored breathing and
lethargy at the 100 mg/kg dose, but was well-tolerated at both 3
and 30 mg/kg. These observations suggested that the toxicity was
related to the peak plasma concentration and that slower infusions
would allow safe administration of higher doses. Catheterized
female CD-1 mice were administered 10-minute IV infusions at
doses of 3, 10, 30 and 75 mg/kg. Although mice that received the
highest dose, 75 mg/kg, had an unsteady gait after the end of
infusion, they recovered within 2–3 hours. All other doses were
well-tolerated when administered as 10-minute IV infusions. The
clinical signs occurred at the end of the infusions, at the same time
as the Cmax concentrations.
Toxicokinetics. The results (Table 1 and Figure 1) show that
IV infusion over 10 minutes resulted in very high Cmax plasma
concentrations of ST-246. The mean Cmax concentration after the
10-minute IV infusion of 75 mg/kg in female CD-1 mice was
238 mg/mL, 3.6-fold higher than the Cmax observed following a
single oral administration of 1000 mg/kg, a 13-fold higher dose, in
female BALB/c mice. For IV infusions, the Cmax occurred, as
would be expected, at the end of the infusions. The Tmax for the
oral doses; however, were observed later, at 2 hours post
administration at all dose levels, indicating prolonged absorption
in mice. Although the maximum plasma concentrations after these
short IV infusions were much higher than after administration of
much higher oral doses (Table 1), the exposure (AUC0–24 hr) was
only 1.5-fold higher for the same two dose groups. Comparison of
the exposure for the 30 mg/kg oral dose to the 10-minute IV
infusion of the same dose showed that ST-246 had approximately
41% bioavailability for that dose. Dose-normalized exposure after
oral administration declined with increasing dose, but the same
trend was not observed after IV administration.
The elimination half-lives were similar for the IV infusion and
oral doses, those for the IV infusions doses ranged from 2.5 to
4.5 hours, while those for the oral doses ranged from 2.2 to
4.5 hours. These values were very close to what has been
consistently observed throughout the oral nonclinical safety
toxicokinetics studies in BALB/c mice (unpublished observation).
Clearance was relatively consistent after IV infusion over the 3–
75 mg/kg dose range, while the apparent clearance after oral
dosing increased approximately 10-fold over the approximately
30-fold dose range. Figure 1 illustrates that even short IV-infusions
in mice provided high plasma concentrations over time similar to
those observed after oral administration, albeit with higher
maximum plasma concentrations.
Rabbit Studies
Tolerability. The tolerability and pharmacokinetics of IV
administration of ST-246 was compared to that of oral
administration in NZW rabbits. Although a preliminary study
had shown that IV bolus administration of 1 mg/kg was well
tolerated, the IV infusion studies results in mice indicated a
potential for a lack of tolerability after rapid IV administration of
the highest doses. Therefore, ST-246 was administered as 5-
minute slow push IV injections at doses of 3, 30, and 60 mg/kg in
NZW rabbits via the marginal ear vein. Whereas the 3 and
30 mg/kg doses were well-tolerated, rabbits administered the
60 mg/kg dose exhibited lethargy, labored breathing and narcosis
immediately following injection. These animals appeared to
recover fully 30–60 minutes after the injections. A slower
(15 minute) infusion of the 3 mg/kg dose was also well-tolerated.
Toxicokinetics. The 60 mg/kg IV dose group had the
highest Cmax concentration, as well as the highest exposure, as
measured by the AUC values (Table 2). Systematic comparison of
the oral and IV Cmax and AUC values for rabbits does not
completely elucidate which parameter, Cmax or AUC, may have
been related to those clinical signs, except that the signs
disappeared coincidently with the rapid decline in plasma
concentrations. The 15-minute IV infusion of 3 mg/kg resulted
in a mean Cmax concentration of 5.79 mg/mL, two-fold higher
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100 mg/kg (Table 2), and there were no observations in either
group. Clinical signs in the rabbits were observed only at the
60 mg/kg dose, where the mean Cmax plasma ST-246
concentration was 94.1 mg/mL, while the mean maximum
plasma concentration observed for the well-tolerated 30 mg/kg
dose of ST-246 was lower, at 38.5 mg/mL. Whereas the Cmax
values for short IV infusions were much higher than that of a
much higher oral dose, 100 mg/kg, the exposures, as determined
by the AUC measurements, were much lower. The AUC0–24
values observed after the 30 mg/kg dose via intravenous slow push
in both genders were comparable to that recorded for the
100 mg/kg oral dosing and in spite of the high Cmax; it was
evident from the cageside observations that this dose and delivery
rate was well tolerated in rabbits. As was observed with mice, short
intravenous infusions in rabbits produced very high maximal ST-
246 concentrations, which corresponded with the time of the
observed clinical signs in the animals. The pharmacokinetic
parameters in rabbits were calculated using the 15-minute IV
infusion of 3 mg/kg ST-246. In the 15-minute IV infusion study,
blood samples were taken immediately at the end of infusion
instead of 5 minutes after the end of infusion as in the initial IV
infusion study. The Cmax from the second study was therefore a
more accurate reflection of Cmax than that of the initial 5-minute
IV infusion study and, in fact, the Cmax values were substantially
higher (See Table 2). The results from the single longer infusion
confirmed what was observed in the shorter infusion study that
evaluated a dose range; that the Cmax values after short IV
infusions were much higher than the values observed after
equivalent oral doses.
The semi-logarithmic graph of the plasma concentration time
curves in rabbit IV infusion studies shows biphasic distribution and
elimination (Figure 2). There appeared to be an initial rapid
distribution phase that was followed by a slower terminal
elimination phase. There was no clear dose-related trend in the
elimination half-lives after IV infusion in rabbits. The elimination
half-lives ranged from approximately 1 hour to 12.2 hours for the
IV infusion dose groups, while the elimination half-life for the
100 mg/kg oral dose was 3.7 hours (Table 2).
NHP Studies
Toxicokinetics. ST-246 was administered via IV infusion
over 4 hours via surgically implanted vascular access ports in NHP
at doses of 1, 3, 10, 20, and 30 mg/kg. The plasma concentrations
Table 1. Comparison of pharmacokinetic parameters for ST-246 after oral administration to female BALB/c mice and 10-minute IV
infusion in female CD-1 mice (parameters at each dose were calculated from concentrations from three individual mice at each
time point, thus no statistical information is available).
Route Dose T1/2 Cmax AUC0–24 hr CL
mg/kg hr mg/mL hr*mg/mL mL/hr/kg
10-min IV Infusion 3 4.5 17 68 43
10 2.8 64 408 25
30 2.5 147 709 42
75 2.8 238 1253 60
Route Dose T1/2 Cmax AUC0–24 hr CL/F
mg/kg hr mg/mL hr*mg/mL mL/hr/kg
PO 30 2.4 38 292 102
100 2.2 44 456 219
300 4.1 64 669 438
1000 4.5 66 852 1133
IV, intravenous.
PO, per oral.
doi:10.1371/journal.pone.0023237.t001
Figure 1. Plasma concentration time curves for oral and IV
administration of ST-246 in mice. The means and standard
deviations of the plasma concentrations over time are shown after
oral administration of ST-246 to female BALB/c mice at doses of 30
(chartreuse hexagons) and 1000 mg/kg (purple squares). The means
and standard deviations of the plasma concentrations over time after
10 minute IV infusions to female CD-1 mice at 3 (red circles), 10 (blue
triangles), 30 (black triangles), and 75 mg/kg (green diamonds). Each
time point is the mean value from three individual mice.
doi:10.1371/journal.pone.0023237.g001
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maximum concentrations at the end of the infusion (Table 3,
Figure 3). The maximum plasma concentrations (Cmax) were
higher after the IV infusions than after oral administration of
equivalent doses (Table 3). At higher doses, the differences
between the oral and IV Cmax concentrations increased. The Cmax
concentrations after oral administration increased less than dose-
proportionally, while the peak plasma concentrations after IV
infusion increased more than would be expected based on dose-
proportionality.
The maximum plasma concentration after oral administration
of ST-246 increased only 37-fold as the dose was increased 100-
fold, from 0.3 to 30 mg/kg, while the exposure (AUCinf-obs)
increased closer to the proportional increase in dose, or 84-fold.
The elimination was also biphasic after oral administration, with
plasma concentration time curves similar to those observed for
rabbits.
The plasma elimination after IV infusion appeared to have at
least two distinct phases, with a rapid distribution phase observed
at the end of the infusion followed by a much slower terminal
elimination phase (Figure 3). The plasma concentrations fell below
the lower limit of quantitation (LLOQ=5.0 ng/mL) before
24 hours for most of the animals in the 1 mg/kg dose group,
but ST-246 was above the LLOQ for all other animals in the
higher dose groups through the last time point at 48 hours.
The pharmacokinetic (PK) parameters were calculated using
non-compartmental analysis for individual animals. For the IV
infusions, each dose group consisted of two males and two females,
while for the oral dose administration; each dose group had three
males and three females. Student’s t-test was performed in order to
evaluate potential gender differences on the PK parameters of
Cmax and AUCinf. There were no statistically significant gender
differences (p.0.05) with respect to the Cmax or AUCinf values at
each dose level tested with a 95% confidence interval. Therefore,
the mean and standard deviation values were calculated by
including all animals from both genders of each dose group. The
variability of individual Cmax or AUCinf values within each dose
group was quite small, with the exception of one or two animals
that had inadvertent and obvious subcutaneous injections and
whose values were excluded from group means (individual data
not shown).
Although the Cmax and AUCinf values increased dose-
proportionally as the 4 hour IV-infused doses increased from 1
to 10 mg/kg, the increases in these values were greater than dose-
proportional at the 20 and 30 mg/kg doses (Table 3). The Cmax
values for the 3 and 10 mg/kg doses were 2.7-fold and 11.5-fold
higher, respectively, than that of the 1 mg/kg dose, while the
corresponding values for the 20 and 30 mg/kg doses were 31-fold
and 52-fold higher, respectively. The AUCinf values increased 3.0,
11.0, 32, and 53-fold higher for the 3, 10, 20, and 30 mg/kg doses,
Table 2. Comparison of pharmacokinetic parameters for ST-246 after oral administration and IV administration to New Zealand
White rabbits.
Route Dose N T1/2 Cmax AUC0–24 hr CL
mg/kg hr mg/mL hr*mg/mL mL/hr/kg
IV Bolus 1 6 0.960.2 1.6762.27 1.4360.40 166062166
15-min IV Infusion 3 4 1.261.1 5.7963.67 3.3961.07 9666363
1IV Slow Push (5-min) 3 4 3.260.0 3.0360.37 2.3860.93 13396521
1IV Slow Push (5-min) 30 4 12.265.8 38.563.7 13.360.7 22296134
1IV Slow Push (5-min) 60 4 5.260.8 94.1611.1 61.868.7 9876138
1Blood draw taken 5 minutes after actual EOI
Route Dose N T1/2 Cmax AUC0–24 hr CL/F
mg/kg hr mg/mL hr*mg/mL mL/hr/kg
PO 100 6 3.763.2 2.8662.03 19.8616.6 720766251
EOI, end of infusion.
IV, intravenous.
PO, per oral.
doi:10.1371/journal.pone.0023237.t002
Figure 2. Plasma concentrations over time after IV and oral
administration in New Zealand White Rabbits. Plasma concen-
trations of ST-246 over time are shown after oral administration of
100 mg/kg (purple squares); bolus IV administration of 1 mg/kg (red
circles); or a 5- minute IV slow push of 3 (blue triangles), 30 (black
triangles), or 60 mg/kg (green diamonds). A 15-minute IV infusion of
3 mg/kg (blue hexagons) is also shown. Each curve is the mean with
standard deviations from two male and two female rabbits.
doi:10.1371/journal.pone.0023237.g002
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exposure above dose-proportionality was also reflected in the
strong trend of decreased clearance as the dose infused over
4 hours was increased (Table 3). Extending the IV infusion length
to 6 hours for the 20 and 30 mg/kg doses increased the clearance
(and decreased exposure) relative to the shorter infusions. The
clearance values for the longer infusions of the higher doses,
however, were still lower than the 1, 3, and 10 mg/kg doses. The
apparent decrease in clearance values with increasing doses were
not statistically significantly different (p.0.05) when evaluated by
ANOVA.
The mean Cmax plasma concentrations were higher for the
4 hour infusions compared to the 6 hour infusions by approxi-
mately 50%, and the exposures calculated for shorter infusions
were also higher, although only by approximately 20%. Plasma
concentrations after the end of infusions appeared to have at least
two phases for all IV infusions, with a rapid distribution phase
clearly observed just after the EOI followed by a slower terminal
elimination phase. The plasma concentration time curves
appeared similar for the two infusion rates and doses, except for
the Tmax and actual plasma concentrations.
The elimination half-lives after IV infusions were relatively
constant over the dose range and different lengths of infusions,
ranging from 6.6 to 9.1 hours (Table 3). Oral administration of the
30 mg/kg dose resulted in a 17.7 hour terminal elimination half-
life, compared to a 9.9 hour half-life for the orally administered
3 mg/kg dose. (This longer half-life was due to a single animal that
had a very long value. If the value for that animal was removed the
mean elimination half-life for the remaining five NHP would have
been approximately 10 hours.) Oral administration of doses of up
to 20 mg/kg had similar elimination half-lives; and these
elimination half-lives were very similar to those observed after
IV infusions (Table 3).
A single day twice-a-day (BID) administration study of the two
highest total daily doses was conducted via two 4 hour IV infusions
initiated12 hoursapartoverasingle24 hourtimeperiod(Figures4A
and 4B). The individual doses were 10 and 15 mg/kg, so that the
total daily doses were 20 and 30 mg/kg/day for the two dose groups,
respectively. Plasmaconcentrations increased over each of the 4 hour
IV infusion periods with the Cmax for most animals occurring at the
end of the infusion. At the last time point, 60 hours after the
beginning of the first IV infusion dose, the ST-246 concentration was
quite close to the lower limit of quantitation (5 ng/mL) for all of the
animalsinbothdosegroups.Thesemi-logarithmicgraphs(Figures4A
and 4B) suggest that ST-246 elimination from the plasma after the
end of the second infusion was at least biphasic, with a rapid
Table 3. Comparison of pharmacokinetic parameters for ST-246 after oral administration and IV infusions in cynomolgus monkeys.
Dose N T1/2 Tmax Cmax AUCINF_obs CL
(mg/kg) (hr) (hr) (mg/mL) (hr*mg/mL) (mL/hr/kg)
4 Hr-IV Infusion
1 4 6.666.0 4 0.3860.11 1.9460.46 5376117
3 4 8.563.2 4 1.0560.19 5.8360.87 523677
10 4 8.661.3 4 4.4060.94 21.363.4 478671
20 4 8.762.5 4 11.862.0 59.6610.1 353659
30 4 7.860.7 4 20.164.2 100618 307659
6 Hr-IV Infusion
20 4 6.662.3 6 7.4860.40 47.966.1 433653
30 4 6.960.8 6 13.961.3 87.2614.6 362661
BID Study 4 Hr IV Infusions SOI 12 Hours Apart - First Dose
10 8 N/A 4 4.5961.29 21.065.0 N/A
15 8 N/A 4 7.3661.47 32.565.7 N/A
BID Study 4 Hr IV Infusions SOI 12 Hours Apart - Second Dose
10 8 8.962.5 4 5.1860.89 26.865.0 429674
15 8 9.162.6 4 9.0860.95 48.767.5 351644
Dose N T1/2 Tmax Cmax AUCINF_obs CL/F
(mg/kg) (hr) (hr) (mg/mL) (hr*mg/mL) (mL/hr/kg)
PO Administration
0.3 6 4.061.3 2.5 0.05460.028 0.3860.15 9206437
3 6 9.966.0 3.3 0.49660.145 4.5360.49 669665
10 6 7.060.9 3.8 1.0860.28 11.863.7 9186275
20 6 7.262.3 3.2 1.7160.71 18.367.0 12086385
30 6 17.7613.8 3.6 1.9960.87 31.967.4 9926281
SOI, start of infusion.
IV, intravenous.
PO, per oral.
BID, twice a day.
doi:10.1371/journal.pone.0023237.t003
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elimination phase for both doses.
The BID administration study had 4 males and 4 females in each
dose group, providing a larger number with which to evaluate any
potential gender differences in the pharmacokinetic parameters
after IV infusion. A student’s t-test analysis of the PK parameters
(Cmax, AUClast or AUCinf,C la n dV ss) showed equivalence for the
two genders, with the exception of the Cmax observed during the
first phase of dosing at the 10 mg/kg/dose level (p,0.05). Because
there were no consistent differences between the pharmacokinetic
parameters for the two genders, the final mean and standard
deviation values for ST-246 were calculated by combining the data
from both genders for each dose group.
The Cmax and AUClast values for the 15 mg/kg dose were 1.6-fold
higher than those of the 10 mg/kg dose during the first 4 hour IV
infusion. During the second IV infusion the increase was slightly
more, approximately 1.8-fold for the both Cmax and AUC values.
The terminal elimination half-lives, calculated from the second
infusion, were essentially identical, 8.9 and 9.1 hours for the two
doses, respectively. Clearance was also essentially equivalent for these
t w od o s e sa n dw i t h i nt h er a n g eo b s e r v e df o rt h es i n g l eI Vi n f u s i o n s .
Tolerability. As was also observed in the IV infusions studies
in mice and rabbits, rapid infusions of the highest doses in NHP,
30 mg/kg infused over 4 hours, resulted in clinical signs,
coincident with the end of the infusion. Three out of four
animals that received the 30 mg/kg dose of ST-246 over the 4-
hour infusion duration exhibited slight generalized tremors. These
tremors were observed within 13 minutes of the end of the
infusion on the day of dosing and resolved approximately 2 hours
after the end of the infusion, indicating reversibility of this toxicity.
Tremors were not observed in animals dosed at 30 mg/kg over
6 hours or in any of the animals that received the 20 mg/kg dose
via either infusion duration. In addition, no clinical signs were
observed throughout the BID study in any of the NHP. The mean
peak plasma concentration for the 30 mg/kg 4-hour infusion
group was 20.0 mg/mL, while the mean peak plasma concen-
tration for the same dose infused over 6 hours was approximately
13.0 mg/mL. The peak plasma concentrations were much lower in
both 20 mg/kg dose groups, as well as the BID study (Table 3).
Discussion
The antiviral efficacy of ST-246 against poxviruses has been
demonstrated after oral administration in mice, rabbits, ground
squirrels, prairie dogs, and NHP [24,28–32,34]. The pharmaco-
Figure 4. Exposure after different dosing regimens of either 20
or 30 mg/kg ST-246 to cynomolgus monkeys. The mean and
standard deviation values for the plasma concentrations over time are
shown for different dosing regimens of (A) 20 mg/kg or (B) 30 mg/kg.
The dosing regimens included oral administration (3 males and 3
females in each dose group, green diamonds), 4 hour IV infusion (2
males and 2 females in each dose group, red circles), 6 hour IV infusion
(2 males and 2 females in each dose group, blue diamonds), and BID
two 4 hour IV infusions initiated 12 hours apart (4 males and 4 females
in each dose group, black diamonds).
doi:10.1371/journal.pone.0023237.g004
Figure 3. ST-246 plasma concentrations over time after oral or
4 hours IV infusions in cynomolgus monkeys. Plasma concentra-
tion of ST-246 after a single oral dose of 3 (chartreuse hexagons), 10
(purple squares), or 30 mg/kg (white circles) compared to the plasma
concentration time curves after 4 hour IV infusion of 1 (red circles), 3
(blue triangles), 10 (black triangles), or 30 mg/kg (green diamonds) in
cynomolgus monkeys. Each curve shows the means and standard
deviations. For oral administration there were 3 males and 3 females in
each dose group while for the IV infusion there were 2 males and 2
females in each dose group.
doi:10.1371/journal.pone.0023237.g003
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characterized in mice, NHP and humans, with limited information
in rabbits, rats, and dogs. A complete understanding of the
pharmacokinetics is important in species in which the efficacy is
also being evaluated, as the selection of the human therapeutic
dose will necessarily be chosen based on the animal PK/PD
relationship, due to the lack of evaluable orthopox disease in
humans.
The similarity of the plasma concentration time profiles after
oral and IV administration demonstrated that IV administration
of a dose of ST-246 should provide efficacy against orthopox-
viruses, assuming the administration is slow enough to avoid what
appeared to be a Cmax-related toxicity. Oral administration of
100 mg/kg provided optimal efficacy in mice against ectromelia
virus [28]. Exposure after the oral 100 mg/kg doses was close to
that measured after the 10 mg/kg IV slow push administration
(Table 1), indicating a reasonable dose at which to start to evaluate
antiviral activity with the IV formulation. Elimination in mice
appeared to be mono-exponential after oral administration, but
appeared to have a very short and rapid distribution phase after
IV administration. Oral administration of ST-246 in mice had not
elicited any dose-limiting toxicity at doses of up to 2000 mg/kg,
although this might have been due to the fact that absorption after
oral administration appeared to be saturated and higher doses in
particular did not result in concomitantly higher peak plasma
concentrations and exposure. The observed dose-limiting toxicity
of unsteady gait and disequilibria after IV administration in mice,
which was observed briefly at the end of the IV infusion, and that
resolved within an hour, suggested that the toxicity might be
related to the maximum plasma concentration. This same type of
toxicity was observed in the rabbit IV infusions, in which the
5 minute infusion of 60 mg/kg was the maximum-tolerated dose.
At the end of the infusion of the 60 mg/kg dose, lethargy, labored
breathing and narcosis were observed. All animals appeared to
fully recover within 30–60 minutes after the end of the infusion,
again, coincident with the rapidly decreasing plasma ST-246
concentrations. Oral administration had not elicited any dose
limiting toxicity at 100 mg/kg in rabbits. In NHP, mild ataxia was
observed in three out of four animals at the end of the 4 hour IV
infusion of the 30 mg/kg dose, but in none of the other doses or
dosing regimens. In fact, ST-246 had been administered orally
daily at 300 mg/kg for as long as three months and had been well-
tolerated at that dose. As was observed in mice and rabbits, the
clinical signs were observed only at the end of the infusion of the
highest dose. In NHP this was at the 30 mg/kg dose administered
over 4 hours, coincident with the peak plasma concentrations, and
resolved after a short period of time.
Taken together, the observations of clinical signs at peak plasma
concentrations in mice, rabbits, and cynomolgus monkeys after IV
infusions of the highest dose level over the shortest time period and
resolution of these toxicities coincident with the decrease in plasma
concentrations strongly indicate that this observed toxicity was
related to the high peak plasma concentrations. Further, the
toxicity appears to be reversible, and was not observed when the
plasma concentrations were kept at lower concentrations by slower
infusion of equivalent doses of ST-246. Although the mechanism
of this toxicity is not yet known, the same ataxia was previously
observed after oral administration of 1000 and 2000 mg/kg doses
in NHP, where the mean Cmax was approximately 20 mg/mL,
similar to that observed after the 4-hour IV infusion of 30 mg/kg
ST-246. This CNS toxicity was also observed at lower doses in the
dog, where the maximum-tolerated dose for repeat dose
administration for ST-246 was 30 mg/kg [34]. A comparison of
the ST-246 concentrations in the CSF and brain between NHP
and dogs after comparable doses showed that the concentrations
were much higher in the dogs, possibly explaining the unique
sensitivity. In each of the species where this toxicity was observed,
further investigations demonstrated that slower infusions eliminat-
ed the clinical observations, indicating that IV infusions in humans
can be conducted safely by initiating any studies with low doses
administered as slow IV infusions.
The plasma concentration time curves in rabbits dropped very
rapidly after the end of the infusion compared to what had been
observed after oral administration, where apparently prolonged
absorption provided a long terminal elimination phase with
relatively high concentrations after a single oral administration of
100 mg/kg (Figure 2). Interestingly, as the IV infused dose was
increased from 30 to 60 mg/kg, the concentration observed during
the terminal elimination phase increased, suggesting that higher
doses may have, as was observed in NHP, saturated some
mechanism of clearance. The rapid decrease in plasma concentra-
tions in rabbits after the end of the infusions suggests prolonged
infusionsmightbe required forefficacy studies inrabbits. Additional
infusions studies would be needed to confirm the potential
relationship between administered dose and clearance in rabbits.
The oral ST-246 study in NHP evaluated the pharmacokinetics
over a dose range which encompassed those used in efficacy
studies, from 0.3 to 30 mg/kg. The results demonstrated that
absorption appeared to be saturated as the orally administered
dose was increased, and this was reflected in both the Cmax
concentrations as well as the exposure. Although the Cmax as well
as the exposure increased over this oral dose range, they increased
less than dose-proportionally. The Cmax increased only 37-fold
over the 100-fold dose increase, while the exposure, as measured
by the AUCinf, increased 84-fold, much closer to the 100-fold dose
increase.
The saturation of absorption, which led to decreased plasma
concentrations and exposure with increasing oral doses, would not
be observed after IV infusions, where absorption is not a
component of the pharmacokinetics. The bioavailability of ST-
246 in NHP based on comparison of identical oral and IV doses
thus ranged from 77% at 3 mg/kg to 31% at 20 and 30 mg/kg
doses. After IV infusions, the exposure at these high doses was
actually higher than would be expected based on dose-propor-
tional exposure. The exposure for the 4 hour IV infusions of 20
and 30 mg/kg were 30-fold and 50-fold higher, respectively, than
the exposure observed after the 1 mg/kg IV infused dose (Table 3).
Longer infusions reduced the Cmax values closer to dose-
proportional for the 20 and 30 mg/kg doses, while the AUC
values decreased to 25-fold and 45-fold higher than the exposure
observed for the 4 hour 1 mg/kg IV infusion (Table 3). The BID
dose regimen confirmed the observation that slower infusions
decreased not only the Cmax, but reduced the total exposure values
to closer to dose proportional. These results suggest that a rapid
rate of infusion of ST-246 may have saturated some clearance
mechanism. Over a similar dose range, oral absorption may have
decreased with increasing dose, so that clearance remained
relatively constant, or even increased slightly.
The plasma concentration time curves in NHP after oral
administration were very similar to those observed after both the 4
and the 6 hour IV infusions, except for the higher peak plasma
concentrations observed after IV administration. The similarity in
the elimination half-lives, as well as the similar plasma concentra-
tions during the terminal elimination phases, suggest that similar
efficacy could be achieved.
Visual inspection of plasma concentration time curves after oral
administration of ST-246 suggests that absorption was prolonged
and may have some impact on the apparent elimination half-lives.
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any of the three species studies between oral and IV administra-
tion, indicating that prolonged absorption did not play a
significant role in the elimination half-lives after oral administra-
tion. Given these similar elimination half-lives across all three
species examined by oral and IV infusions, it appears that longer
IV infusions should be administered in order to reduce the high
plasma concentrations, and to avoid the coinciding toxicity, while
continuing the once daily dosing regimen that is currently being
used in oral studies.
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